ScottKopetzMDPhD

Oncology • Houston, TX

Gastrointestinal Medical Oncology at MD Anderson Cancer Center

Join to view full profile

Dr. Kopetz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kopetz's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas, Graduate School of Biomedical SciencesPhD, Cancer Biology, 2005 - 2009
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Johns Hopkins University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2027
TN State Medical License 2022 - 2026
TX State Medical License 2004 - 2026
AL State Medical License 2022 - 2025
GA State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
OK State Medical License 2020 - 2025
WA State Medical License 2022 - 2025
NC State Medical License 2001 - 2004
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 3
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients Start of enrollment: 2005 Jan 01
Completed
Phase 2
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer Start of enrollment: 2007 Apr 23
Completed
Phase 1
Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol Start of enrollment: 2010 Aug 01
Completed
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2013 Mar 01
Completed
Phase 2
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2014 Nov 01
Completed
Phase 2
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Start of enrollment: 2018 Nov 29
Terminated
Phase 2
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Start of enrollment: 2019 Oct 29
COMPLETED
PHASE2
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Start of enrollment: 2019 Jul 22
ACTIVE_NOT_RECRUITING
PHASE1
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease Start of enrollment: 2021 Oct 12
RECRUITING
NA
Roles: Contact, Principal Investigator
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) Start of enrollment: 2022 Aug 04
RECRUITING
PHASE1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.
Caiming Xu, Alessandro Mannucci, Francis Esposito, Helena Oliveres, Vicente Alonso-Orduña
Clinical Cancer Research. 2025-03-17
1 citations
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomise...
Bruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, Brian M Anderson, Caleb S O'Connor
The Lancet. Gastroenterology & Hepatology. 2025-03-13
2 citations
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim
Nature Medicine. 2025-03-01

Journal Articles

Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge
B Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology
Colorectal Premalignancy Is Associated with Consensus Molecular Subtypes 1 and 2
L M Ellis, P M Lynch, J A Willis, S Kopetz, Annals of Oncology
DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Scott Kopetz, Michael T Tetzlaff, Michael J Overman, Huamin Wang, Clinical Cancer Research

Press Mentions

Lifesaving Cancer Study Delivers Complete Remission for All Trial PatientsMarch 6th, 2025
Dual-Targeted Therapies plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRCFebruary 5th, 2025
Study Finds New Standard-of-Care for Treatment-Naïve, Aggressive Colorectal CancerJanuary 29th, 2025
Join now to see all

Grant Support

Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancerMASSACHUSETTS GENERAL HOSPITAL2022–2027
Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
MDACC-PREDICTUNIVERSITY OF TX MD ANDERSON CAN CTR2020–2025
MD Anderson Cancer Center SPORE in Gastrointestinal CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2019–2025
Colorectal Cancer Molecular Subtype Assay Development and ValidationUNIVERSITY OF TX MD ANDERSON CAN CTR2018–2025